Prof. Mustafa ÖZGÜROĞLU
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit | Research profile
Madridge Publishers - Open Access Journals
Mustafa Özgüroğlu - Professor of Medical Oncology - Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine | LinkedIn
Mustafa Ozguroglu (@mozguroglu) / Twitter
Immunotherapy and Targeted Therapies in NSCLC: Phase 3 Data From ESMO 2022 - Cancer Therapy Advisor
Mustafa Özgüroğlu - Professor of Medical Oncology - Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine | LinkedIn
Acıbadem Mehmet Ali Aydınlar Üniversitesi Kütüphanesi s19.2
Title of the study: Phase II Clinical Study Evaluating the Efficacy and Safety of Weekly Docetaxel and Four Weekly Carboplat
Dr. Ozguroglu on the Individualization of Treatment in NSCLC
Award Ceremony Held for Faculty Members Included in the World's Most Influential Scientists List
Mustafa Özgüroğlu (mzgrolu) - Profile | Pinterest
Prof. Dr. Mustafa Özgüroğlu - Yorumları incele ve randevu al | DoktorTakvimi.com
Dr. Philip A. Philip, MD | Detroit, MI | Oncologist | US News Doctors
Akademik | Prof.Dr.Gökhan Demir
Prof.Dr. Özcan YILDIZ | Doktorlarımız | Medipol Sağlık Grubu
Prof. Jair Bar | Tel Aviv University
Prof.Dr. MUSTAFA ÖZGÜROĞLU | AVESİS
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit | Research profile
Mustafa Ozguroglu - AI Profile | 人才画像- AMiner
YILIN EN BAŞARILI ONKOLOJİ UZMANI – Türkiye Ödülleri
YILIN EN BAŞARILI ONKOLOJİ UZMANI – Türkiye Ödülleri
taflan salepçi kimdir 2ILJK5
How to get to Prof Dr Önder Kılıçoğlu Muayenehanesi in Nişantaşı, Şişli by Bus, Metro or Cable Car?
Mustafa Özgüroğlu - Professor of Medical Oncology - Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine | LinkedIn
Award Ceremony Held for Faculty Members Included in the World's Most Influential Scientists List
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial - The Lancet Oncology
